News Releases | PepGen

Year

16 Jun '22

PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON , June 16, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for

05 May '22

PepGen Announces Pricing of Initial Public Offering

BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of its initial public

06 Apr '22

PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

Initiation of Phase 1 Study Marks PepGen’s Transition to a Clinical Stage Company This Phase 1 Healthy Normal Volunteer (HNV) Study will Evaluate Safety and Tolerability as the Primary Objective, and will Begin to Evaluate the Delivery and Target Engagement of PGN-EDO51 to Enable Subsequent

05 Apr '22

PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development

Dr. Mellion brings deep experience in neuromuscular disease research and treatment as a biopharma executive, researcher and physician BOSTON, April 5, 2022 – PepGen, Inc., a company developing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe

30 Mar '22

PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology

BOSTON, March 30, 2022 – PepGen, Inc., advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, today announced that it has appointed Jennifer Cormier as Senior Vice President, Clinical Operations and Dr.

15 Mar '22

PepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy

Updates on preclinical data and the clinical development plan will be presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference BOSTON, March 15, 2022 – PepGen Inc., a company advancing the next generation of oligonucleotide therapies for neuromuscular and neurologic

19 Jan '22

PepGen Appoints Laurie Keating as Chair of Board of Directors

Keating brings strong experience as a life science executive and Board member BOSTON, January 19, 2022 – PepGen, Inc. , a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the